Statins: balancing benefits, efficacy and safety.

摘要: Coronary heart disease (CHD) is the leading cause of death in US. The risk CHD substantially increased people with elevated levels low-density lipoprotein cholesterol (LDL-C). 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) are most effective drug class for lowering LDL-C. Long-term prospective studies have shown that statin therapy significantly reduces morbidity and mortality patients without or evidence established (primary secondary prevention, respectively). In 1988, treatment guidelines were first issued by National Cholesterol Education Program Adult Treatment Panel I (NCEP-ATP I), then revised 1993 (ATP II), to provide recommendations prevention management high adults. Despite these guidelines, recent national surveys therapies being under-utilised they often fail achieve LDL-C goals NCEP-ATP II. reasons appear be ...